Zipsor

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Zipsor

What is Zipsor

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a type of non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation. It works by blocking enzymes, called cyclooxygenases (COX), which produce substances that cause pain and swelling. It is usually prescribed to treat acute and chronic pain from various causes, and is sometimes combined with a stomach-protecting drug called misoprostol to reduce the risk of stomach ulcers. Diclofenac was first approved for use by the FDA in 1988 under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Zipsor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Zipsor Affects Patients

Diclofenac helps reduce pain and fever by reducing inflammation. Unfortunately, it also decreases the amount of protective mucus in the stomach, making it more likely to develop an ulcer.

How Zipsor works in the body

Diclofenac works by blocking the production of molecules called prostaglandins. These molecules are involved in pain and inflammation, so reducing their production reduces these symptoms. Diclofenac also reduces inflammation by preventing white blood cells from entering the affected area and blocking molecules that assist in cell reproduction. It also works on receptors in the brain to reduce fever. All these pathways work together to reduce inflammation and pain.

When to interrupt dosage

The proposed measure of Zipsor is contingent upon the identified condition, for example Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The quantity of dosage is contingent upon the execution strategy (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) featured in the following table.

Condition

Dosage

Administration

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Muscle Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Fever

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Surgery, Dental

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Osteoarthritis of the Knee

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Sprains and Strains

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Wounds, Nonpenetrating

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Musculoskeletal System

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid - Topical, Liquid, Gel, Gel - Topical, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Tablet - Oral, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system, Drug delivery system - Topical

Warnings

Zipsor Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Zipsor.

Common Zipsor Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Zipsor Toxicity & Overdose Risk

Overdosing on Voltaren can lead to symptoms such as fatigue, nausea, vomiting, upper abdominal pain, and bleeding from the digestive tract. In rare cases, patients may experience high blood pressure, kidney damage or failure, shallow breathing, or coma. Treatments for Voltaren overdose include inducing vomiting and activated charcoal, as long as the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Zipsor Novel Uses: Which Conditions Have a Clinical Trial Featuring Zipsor?

491 active clinical trials are currently in progress to assess the effectiveness of Zipsor in alleviating Inflammation, Argon Laser Trabeculoplasty and Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

59 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3

Osteoarthritis of the Knee

78 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

118 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

20 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

2 Actively Recruiting

Phase 4, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

5 Actively Recruiting

Not Applicable

Pain

2 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Zipsor Reviews: What are patients saying about Zipsor?

5

Patient Review

8/30/2013

Zipsor for Inflammation of the Sac Surrounding the Joint - Bursitis

Arthroscopic surgery on both knees led to a diagnosis of Pes anserine bursitis, which was incredibly painful and made it hard to walk. Zipsor relieved the pain and swelling quickly. Even though my insurance doesn't cover the cost, I would still use this medication as needed because it is effective.

5

Patient Review

11/4/2013

Zipsor for Inflammation of the Sac Surrounding the Joint - Bursitis

Zipsor is a really great medication that helps me a lot when the weather changes or if I overdo it with my workout. It's been really helpful in reducing swelling and restoring flexibility to my ankle, which was severely damaged 2.5 years ago. The liquid capsules are much better than the regular tablets, since they don't upset my stomach.

5

Patient Review

11/4/2013

Zipsor for Migraine Headache

I take this for extreme migraines. This is the 3rd medication I've tried and the only one that works.

5

Patient Review

9/5/2017

Zipsor for Pain

This medication has been an absolute wonder for me. It takes care of all my fibromyalgia pain as well as any other aches and pains that I experience. Just be careful to follow the dosing instructions.

5

Patient Review

8/2/2013

Zipsor for Pain

This treatment is pretty effective; it takes away the pain about 75% of the time.

5

Patient Review

8/15/2013

Zipsor for Inflammation of the Sac Surrounding the Joint - Bursitis

Zipsor is the only medication I've found in the past year that has helped me with my arm pain. It's been four days and I'm feeling great, no side effects yet!

4.7

Patient Review

9/20/2013

Zipsor for Joint Damage causing Pain and Loss of Function

The price tag is my only problem with this drug. I'll be looking for something more affordable with my next prescription.

4.3

Patient Review

3/3/2014

Zipsor for Pain

Worked just as well for me as Ibuprophen800, but it's too expensive. Not covered on my new insurance plan. They want me to try Diclofenac

4

Patient Review

12/16/2012

Zipsor for Pain

This drug was much more effective than others I've tried for my lower back pain. The only issue is that it's quite expensive and my insurance doesn't cover it, so I may have to stop using it.

4

Patient Review

5/25/2013

Zipsor for Rheumatic Disease causing Pain & Stiffness in Backbone

I find that this medication is really effective, and I can take it multiple times a day without any issues.

3.3

Patient Review

9/6/2012

Zipsor for Joint Damage causing Pain and Loss of Function

This medicine was effective in reducing my post-operative ankle pain and swelling. However, it comes with the significant side effect of anxiety for me.

3.3

Patient Review

6/24/2013

Zipsor for Pain

I think this medication is great, but my pharmacist says it's too expensive for most people. I pay $100 a month out of pocket, so I get why he feels that way. Hopefully the manufacturer will do something to make it more accessible in the future.

2.3

Patient Review

11/16/2013

Zipsor for Inflammation of the Sac Surrounding the Joint - Bursitis

I didn't find this effective for pain relief, unfortunately. I'm hoping it at least helps with the swelling and my range of motion.

2.3

Patient Review

2/22/2014

Zipsor for Gout

I was given this drug for gout pain, but it didn't seem to help very much.

2

Patient Review

11/13/2012

Zipsor for Joint Damage causing Pain and Loss of Function

I saw some benefits initially, but they quickly faded after starting this treatment.

2

Patient Review

9/6/2013

Zipsor for Pain

I had foot surgery, then my foot got infected and still hurts really badly. I also have herniated disks in my back with scoliosis and arthritis, and this does nothing for any of those pains either.

2

Patient Review

11/21/2012

Zipsor for Joint Damage causing Pain and Loss of Function

I unfortunately had an allergic reaction to this that required medical attention.

1.7

Patient Review

8/14/2013

Zipsor for Pain

This NSAID is really expensive, and it's not even as effective as ibuprofen! I don't understand how this drug stays in business.

1.3

Patient Review

2/6/2013

Zipsor for Migraine Headache

I didn't find this to be an effective treatment for migraines. After using it twice, my migraine was still there.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zipsor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How often can you take Zipsor?

"This difference should be taken into consideration when changing strengths or formulations of diclofenac. The only approved dosing regimen for ZIPSOR is 25 mg four times a day."

Answered by AI

What is Zipsor medication used for?

"The text is discussing the drug Zipsor, which is a prescription NSAID. It is used for relief of mild-to-moderate pain in adults."

Answered by AI

What is Zipsor similar to?

"Relafen and Zipsor are NSAIDs used to treat pain, with Relafen being usd more for inflammation and pain caused by arthritis while Zipsor is used more for relief of mild to moderate acute pain."

Answered by AI

What is the difference between Zipsor and diclofenac?

"Zipsor is an NSAID that works by reducing substances in the body that cause pain and inflammation. Zipsor capsules are used to treat mild to moderate acute pain in adults and pediatric patients 12 years of age or older."

Answered by AI

Clinical Trials for Zipsor

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+
All Sexes
Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting
Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Have you considered Zipsor clinical trials?

We made a collection of clinical trials featuring Zipsor, we think they might fit your search criteria.
Go to Trials
Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Image of Resilient Roots: Functional Medicine in Charlottesville, United States.

Ketogenic and Carnivore Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

18 - 64
All Sexes
Charlottesville, VA

This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative colitis and Crohn's disease\] (IBD) or rheumatoid arthritis (RA). Participants will be randomized into one of three groups: 1) Ketogenic Diet, 2) Carnivore (Lion) Diet or 3) Wait-List Control. Participants randomized to a dietary group (ketogenic diet or carnivore diet) will be provided guidance on their specific dietary therapy and answer questions about their symptoms and quality of life at different intervals over a 24 week period. Participants will also complete laboratory testing at different intervals to assess for changes in nutritional status, cardiometabolic health and markers of immune activation and inflammation. Participants initially placed on the wait-list group will be asked similar questions about their symptoms and quality of life and complete the same laboratory testing as participants in a dietary group. Participants on the wait list will then be compared to participants following a specific dietary pattern to assess for any differences between the 2 groups. After 12 weeks, participants on the wait list will be randomized to a dietary group (ketogenic diet or carnivore diet) and followed in a similar fashion for an additional 12 week period.

Recruiting
Has No Placebo

Resilient Roots: Functional Medicine

Robert D Abbott, MD

Have you considered Zipsor clinical trials?

We made a collection of clinical trials featuring Zipsor, we think they might fit your search criteria.
Go to Trials
Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Image of Marquette University in Milwaukee, United States.

Exercise for Pain

35 - 65
All Sexes
Milwaukee, WI

The goal of this clinical trial is to determine how male and female former athletes experience pain and respond to moderate-intensity exercise (strength versus aerobic) compared with both current master's athletes and nonathletes. The main questions this study aims to address are: 1. How do former athletes, master's athletes, and nonathletes experience pain? 2. How do different types of moderate-intensity exercise (strength versus aerobic exercise) influence pain in former athletes, master's athletes, and nonathletes? Participants will complete 3 different testing sessions: 1. Baseline testing including assessments of strength, cardiorespiratory fitness, and pain; 2. Strength exercise: pain assessments will occur before and after moderate-intensity strength training exercise; 3. Aerobic exercise: pain assessments will occur before and after moderate-intensity aerobic exercise. There will be a washout period of approximately one week or greater between each of the three different testing sessions. The order of conditions (strength versus aerobic exercise) will be randomized (crossover randomized trial design).

Recruiting
Has No Placebo

Marquette University

Jacob J Capin, DPT, PhD

Have you considered Zipsor clinical trials?

We made a collection of clinical trials featuring Zipsor, we think they might fit your search criteria.
Go to Trials